The treatment of focal and segmentary glomerulosclerosis;Tratamiento de la glomeruloesclerosis segmentaria y focal

Nefrologia

Volumn 25, Issue 6, 2005, Pages 612-621

  Praga, Manuel ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DECISION TREE; FOCAL GLOMERULOSCLEROSIS; HUMAN; OBESITY; REVIEW;

DECISION TREES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; OBESITY;

EID: 33646595349     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. D'Agati V: The many masks of focal segmental glomerulosclerosis. Kidney Int 46: 1223-1241, 1994.
2. Novick AC, Gephardt C, Guz B, Steinmuller D, Tubbs RR: Long-term follow-up after partial removal of a solitary kidney. N Engl J Med 325: 1058-1062, 1991.
3. Argueso LR, Ritchey ML, Boyle ET, Milliner DS, Bergstralh EJ, Kramer SA: Prognosis of patients with unilateral renal agenesis. Pediatr Nephrol 6: 412-416, 1992.
4. Praga M, Bornstein B, Andrés A, Arenas J, Oliet A, Montoyo C, Ruilope LM, Rodicio JL: Nephrotic proteinuria without hypoalbuminemia: clinical characteristics and response to angiotensin-converting enzyme inhibition. Am J Kidney Dis 17: 330-338, 1991.
5. Praga M, Morales E, Herrero JC, Pérez Campos A, Domínguez-Gil B, Alegre R, Vara J, Martínez MA: Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 33: 52-58, 1999.
6. Kambham N, Markowitz G, Valeri AM y cols.: Obesity-related glomerulopathy: an emerging epidemic. Kidney Int 59: 1498-1509, 2001.
7. Praga M, Hernández E, Morales E y cols.: Clinical features and long-term outcome of obesity-associated focal segmental glomerulosclerosis. Nephrol Dial Transplant 16: 1790-1798, 2001.
8. Chagnac A, Weinstein T, Korzets A, y cols.: Glomerular hemodynamics in severe obesity. Am J Physiol 278: F817-F822, 2000.
9. Chagnac A, Weinstein T, Herman M, Hirsh J, Gafter U, Ori Y. The effects of weight loss on renal function in patients with severe obesity. J Am Soc Nephrol 14: 1480-1486, 2003.
10. Foster MH, Sant GR, Donohoe JF, Harrington JT: Prolonged survival with a remmant kidney. Am J K id ney Dis 17: 261-265, 1991.
11. Praga M, Hernández E, Herrero JC y cols.: Influence of obesity on the appearance of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 58: 2111-2118, 2000.
12. González E, Gutiérrez E, Morales E y cols.: Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remmant kidney. Kidney Int 68: 263-270, 2005.
13. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int 57: 1803-1817, 2000.
14. Hebert LAQ, Wilmer WA, Falkenhain ME y cols.: Renoprotection: one or many therapies? Kidney Int 59: 1211-1226, 2001.
15. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T: Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361: 117-124, 2003.
16. Morales E, Valero MA, León M, Hernández E, Praga M: Beneficial effects of weight loss in overweight patients with chronic proteinuric nephropathies. Am J K id ney Dis 41: 319-327, 2003.
17. Praga M: Slowing the progression of renal failure. Kidney Int 61 (Supl. 80): S18-S22, 2002.
18. Praga M, Hernández E, Montoyo C, Andrés A, Ruilope LM, Rodicio JL: Long-term beneficial effects of ACE inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 20: 240-248, 1992.
19. Korbet SM: Angiotensin antagonists and steroids in the treatment of focal segmental glimerulosclerosis. Semin Nephrol 23: 219, 2003.
20. Praga M, Andrade CF, Luño J y cols.: Antiproteinuric efficacy of losartan in comparison with amlodipine in non-diabetic proteinuric renal diseases: a double-blind, randomized clinical trial. Nephrol Dial Transplant 18: 1806-1813, 2003.
21. Korbet SM, Schwartz MM, Lewis EJ: Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 23: 773, 1994.
22. Rydel, JJ, Korbet, SM, Borok, RZ, Schwartz, MM: Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 25: 534, 1995.
23. Eddy AA, Symons J: Nephrotic syndrome in childhood. Lancet 362: 629-644, 2003.
24. Niaudet P, for the French Society of Pediatric Nephrology: Treatment of childhood steroid resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. J Pediatr 125: 981, 1994.
25. Ponticelli C, Rizzoni G, Edefonti A y cols. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 43: 1377, 1993.
26. Cattran DC, Appel GB, Hebert LA, y cols for the North American Nephrotic Syndrome Study Group. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int 56: 2220, 1999.
27. Meyrier A, Noel LH, Auriche P y cols.: Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Kidney Int 45: 1446, 1994.
28. Segarra A, Vila J, Pou L y cols.: Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or-dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 17: 655, 2002.
29. McCauley J, Shapiro R, Ellis D y cols.: Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 8: 1286, 1993.
30. Duncan N, Dhaygude A, Owen J y cols.: Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 19: 3062-7, 2004.
31. Choi MJ, Eustace JA, Giménez LF y cols.: Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 61: 1098, 2002.
32. Day CJ, Cockwell P, Lipkin GW y cols.: Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 17: 2011, 2002.
33. Schulman SL, Kaiser BA, Polinsky MS y cols.: Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 113: 996, 1998.
34. Heering P, Braun N, Mullejans R y cols.: Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 43: 10-18, 2004.
35. Mitwalli AH: Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 13: 1524, 1998.
36. Caridi G, Bertelli R, Carrera A y cols.: Prevalence, genetics, and clinical features of patients carrying podocin mutations in steroid-resistant nonfamilial focal segmental glomerulosclerosis. J Am Soc Nephrol 12: 2742, 2001.
37. Rana K, Isbel N, Buzza M, Dagher H: Clinical, histopathologic, and genetic studies in nine families with focal segmental glomerulosclerosis. Am J K id ney Dis 41: 1170, 2003.
38. Benzing T: Signaling at the slit diaphragm. J Am Soc Nephrol 15: 1382-1391, 2004.
39. Caridi G, Bertelli R, Di Duca M y cols.: Broadening the spectrum of diseases related to podocin mutations. J Am Soc Nephrol 14: 1278-1286, 2003.
40. Ruf RG, Lichtemberger A, Karle SM y cols.: Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome. J Am Soc Nephrol 15: 722-732, 2004.
41. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G: Blocking Angiotensin II Synthesis/Activity Preserves Glomerular Nephrin in Rats with Severe Nephrosis. J Am Soc Nephrol 12: 941-948, 2001.